Unveiling 5 Analyst Insights On Editas Medicine
Portfolio Pulse from Benzinga Insights
Over the past three months, 5 analysts have evaluated Editas Medicine (NASDAQ:EDIT), with opinions ranging from bullish to bearish. The average 12-month price target has decreased by 25.93% to $10.0. Analysts have adjusted their ratings and price targets in response to market conditions and company performance.
June 18, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Analysts have mixed views on Editas Medicine, with a notable decrease in the average 12-month price target to $10.0. Recent ratings include a mix of 'Perform', 'In-Line', 'Buy', and 'Equal-Weight'.
The decrease in the average 12-month price target and the mixed ratings from analysts suggest a bearish short-term outlook for Editas Medicine. The adjustments in ratings and price targets reflect concerns about the company's financial performance and market conditions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100